Last updated: August 24, 2026
HEMABATE is the branded injectable form of carboprost tromethamine, a prostaglandin analogue used primarily to control postpartum hemorrhage caused by uterine atony and for selected second-trimester pregnancy termination procedures. Its commercial profile is mature: core patent exclusivity has expired, generic carboprost products compete with the brand, and Pfizer does not separately report HEMABATE revenue.
The product remains strategically relevant because it is an injectable uterotonic used in acute-care settings where therapeutic substitution can be constrained by clinical protocols, hospital formularies, and supply availability. Its financial trajectory is therefore driven less by patent protection and more by childbirth volumes, postpartum hemorrhage incidence, hospital purchasing, manufacturing continuity, generic competition, and periodic injectable-drug shortages.
What is HEMABATE and how is it used?
HEMABATE contains carboprost tromethamine at a concentration of 250 micrograms per milliliter. It is administered by intramuscular injection or direct intramyometrial injection under clinical supervision.
| Attribute |
HEMABATE profile |
| Active ingredient |
Carboprost tromethamine |
| Drug class |
Prostaglandin analogue; uterotonic |
| Primary indication |
Postpartum hemorrhage due to uterine atony that has not responded to conventional management |
| Additional labeled use |
Second-trimester termination of pregnancy in specified clinical circumstances |
| Dosage form |
Sterile injectable solution |
| Typical strength |
250 mcg/mL |
| Primary setting |
Hospitals, labor and delivery units, operating rooms, emergency obstetric care |
| FDA pathway |
Original new drug application followed by generic ANDA competition |
| Exclusivity status |
Mature, post-exclusivity product |
| Biosimilar exposure |
None; carboprost is a small molecule, not a biologic |
The product’s clinical value comes from its use as a rescue uterotonic. Standard treatment for uterine-atony bleeding often begins with uterine massage and oxytocin. Other pharmacologic options include methylergonovine and misoprostol. Carboprost is commonly used when initial treatment is inadequate or contraindicated.
The label identifies asthma and significant pulmonary disease as important safety considerations. Other contraindications and precautions include hypersensitivity, active cardiac, pulmonary, renal, or hepatic disease, depending on the clinical context and route of use.[1]
When does HEMABATE lose exclusivity?
HEMABATE lost meaningful market exclusivity decades ago. The product was approved in the era before modern Hatch-Waxman exclusivity structures became the primary determinant of generic entry for new small-molecule drugs. Its active ingredient and dosage form are mature, and generic carboprost products have been approved in the United States.
No current commercial thesis depends on HEMABATE retaining composition-of-matter exclusivity. The relevant competitive questions are manufacturing capacity, FDA approval status, supply reliability, contract pricing, and hospital formulary position.
What patents protect HEMABATE?
Publicly available product information does not indicate an active patent estate that materially restricts generic carboprost entry. Any original composition, formulation, or use patents associated with carboprost or the branded product would have expired long before the current market period.
The commercial protection profile is therefore:
| Protection category |
Current relevance |
| Composition-of-matter patent |
Expired |
| Core formulation patent |
Expired or commercially immaterial |
| Method-of-use patent |
No current barrier to approved generic use |
| Pediatric exclusivity |
Not a current market barrier |
| Orphan exclusivity |
Not applicable |
| Regulatory exclusivity |
Expired |
| Manufacturing know-how |
Potentially relevant to supply reliability, but not an exclusivity right |
The principal intellectual-property issue is not patent infringement risk. It is whether a manufacturer can produce a sterile injectable consistently, obtain FDA approval, and maintain supply through a specialized hospital distribution channel.
What is the FDA and Orange Book status of HEMABATE?
HEMABATE is an FDA-approved prescription injectable marketed under an NDA. FDA labeling identifies the product as carboprost tromethamine injection and states its obstetric indications, dosing, contraindications, and warnings.[1]
The Orange Book framework remains relevant because approved generic carboprost products may rely on the reference product’s safety and efficacy findings through an abbreviated new drug application. Since HEMABATE is a mature small-molecule product:
- There is no active new-drug exclusivity blocking ANDA approval.
- There is no biosimilar pathway because carboprost is not a biologic.
- Paragraph IV litigation is not the principal current risk.
- Generic competition is established rather than prospective.
- Product-specific patent listings do not appear to create a meaningful barrier to market entry.
The practical FDA risk is manufacturing compliance. Sterile injectable products face higher operational and regulatory risk than many oral solid-dose generics because failures involving container closure, sterility assurance, particulates, or facility controls can disrupt supply.
How many patents cover HEMABATE?
No active patent portfolio appears to provide meaningful commercial protection for HEMABATE in the United States. The relevant protection count for current strategy is effectively zero for blocking patents.
That does not mean the product has no technical barriers. Carboprost injection requires:
- Sterile manufacturing and validated aseptic processes.
- Control of degradation and product stability.
- Appropriate container-closure systems.
- Reliable cold-chain or controlled distribution practices where required.
- FDA-compliant labeling and pharmacovigilance.
- Manufacturing capacity capable of serving concentrated hospital demand.
These are manufacturing and regulatory barriers, not enforceable exclusivity rights. They can support pricing during shortages but do not prevent a capable generic manufacturer from entering.
Which companies compete with HEMABATE?
Competition occurs at two levels: direct carboprost competition and therapeutic substitution among uterotonics.
Direct competitors
Generic carboprost tromethamine injection is the direct substitute for HEMABATE. Generic injectable manufacturers and hospital suppliers may compete through:
- Lower acquisition cost.
- Group purchasing organization contracts.
- Guaranteed allocation.
- Backorder performance.
- National distribution coverage.
- Hospital-specific rebate structures.
Public sources do not provide a consistent, product-level market-share series separating HEMABATE from all generic carboprost suppliers.
Therapeutic competitors
| Product |
Active ingredient |
Role in postpartum hemorrhage |
Competitive effect |
| Pitocin |
Oxytocin |
Common first-line uterotonic |
Reduces carboprost use as initial therapy |
| Methergine |
Methylergonovine |
Uterotonic used in selected patients |
Substitute when clinically appropriate |
| Cytotec |
Misoprostol |
Uterotonic, including settings where injectables are less practical |
Low-cost alternative |
| HEMABATE |
Carboprost tromethamine |
Rescue therapy for uterine atony |
Retains value when other agents fail or are unsuitable |
| Tranexamic acid |
Tranexamic acid |
Antifibrinolytic adjunct in postpartum hemorrhage |
Competes for treatment budget but does not directly replace a uterotonic mechanism |
HEMABATE is differentiated by potency and rescue use, but its asthma warning limits use in some patients. Oxytocin has broader first-line use, while misoprostol is easier to store and administer in some resource-constrained settings.
What drives HEMABATE market demand?
The addressable market is linked to deliveries rather than chronic prescription prevalence. Key demand variables include:
- Annual births and delivery volume.
- Incidence of postpartum hemorrhage.
- Hospital protocols for uterine atony.
- Adoption of standardized hemorrhage carts and emergency kits.
- Use of carboprost before surgical intervention.
- Generic availability and contract pricing.
- International maternal-health programs.
- Obstetric care concentration in hospitals and tertiary centers.
The World Health Organization identifies postpartum hemorrhage as a leading cause of maternal mortality and recommends rapid, protocol-driven management.[2] The American College of Obstetricians and Gynecologists also recognizes uterotonics, including carboprost, as part of the treatment framework for postpartum hemorrhage.[3]
Demand is relatively inelastic during an active hemorrhage. A hospital may reduce routine inventory or switch suppliers, but it generally must maintain access to an effective rescue uterotonic. That supports baseline demand even after patent expiry.
What is the financial trajectory for HEMABATE?
Pfizer does not publicly report HEMABATE revenue as a separate line item in its annual reports. The product is grouped within broader pharmaceutical portfolios, and available public filings do not establish a reliable standalone revenue history.
The financial trajectory can nevertheless be characterized:
| Period |
Commercial condition |
Financial implication |
| Launch and early lifecycle |
Branded product with limited direct competition |
Higher branded pricing and stronger product control |
| Patent-expiry period |
Generic entry becomes possible |
Price and share pressure |
| Mature generic period |
Multiple suppliers and hospital contracting |
Lower unit economics; volume and supply continuity matter |
| Shortage or constrained-supply periods |
Fewer reliable suppliers or manufacturing interruptions |
Temporary pricing support and elevated strategic value |
| Current market |
Low-growth, essential injectable product |
Stable demand with limited standalone revenue visibility |
HEMABATE is unlikely to be a major revenue driver for Pfizer relative to oncology, vaccines, inflammation, rare disease, or other high-value pharmaceutical franchises. Its economic value is more likely tied to portfolio contribution, hospital-channel presence, and supply continuity than to high-margin patent-protected sales.
The product may generate attractive returns for a generic supplier if manufacturing costs remain controlled and supply reliability supports premium contracting. The market is less attractive if several approved suppliers compete aggressively on price or if sterile manufacturing requirements create persistent quality and capacity costs.
What generic entry risks exist for HEMABATE?
Generic entry risk is already realized rather than pending. The principal commercial risk to the branded product is substitution by FDA-approved carboprost injection.
Generic launch scenarios
| Scenario |
Likely market effect |
| Two or more reliable generic suppliers |
Sustained price compression and declining brand share |
| One dominant generic supplier |
Lower brand share, but potential supply-based pricing resilience |
| Generic shortage or recall |
Temporary recovery in brand demand and hospital allocations |
| Multiple supplier shortages |
Elevated prices, emergency procurement, and formulary substitutions |
| New low-cost entrant |
Additional contracting pressure and lower average selling price |
| Manufacturing-quality failure |
Market disruption, possible recall, and accelerated switching |
Paragraph IV litigation is not a material forward-looking catalyst for HEMABATE because the relevant patent barriers have expired. Litigation risk is more likely to involve product liability, manufacturing compliance, labeling, supply contracts, or alleged anticompetitive conduct than an Orange Book patent challenge.
What patent litigation affects HEMABATE?
No major active patent litigation is publicly identified as a central commercial issue for HEMABATE. The product’s patent estate is too mature for a conventional branded-versus-generic Paragraph IV dispute to define current market access.
Potential legal exposure instead includes:
- Product liability claims involving maternal or fetal outcomes.
- Failure-to-warn allegations concerning asthma or cardiovascular risks.
- Manufacturing-defect claims involving sterile injectable quality.
- Contract disputes with distributors or group purchasing organizations.
- Regulatory enforcement arising from current good manufacturing practice deficiencies.
- Labeling disputes involving approved indications or administration routes.
These matters can affect cost, reputation, supply, and hospital purchasing, but they do not restore patent exclusivity.
How does HEMABATE compare with other postpartum hemorrhage drugs?
HEMABATE occupies a specialized rescue position rather than the broadest first-line market.
| Commercial factor |
HEMABATE |
Oxytocin |
Misoprostol |
Methylergonovine |
| Typical role |
Rescue uterotonic |
First-line uterotonic |
Alternative or adjunct |
Alternative uterotonic |
| Administration |
Injection |
Injection or infusion |
Oral, sublingual, rectal or other routes depending on use |
Injection or oral |
| Patent strength |
Mature, expired |
Mature, expired |
Mature, expired |
Mature, expired |
| Generic competition |
High |
High |
High |
High |
| Acute-care value |
High when indicated |
Very high |
Moderate to high |
High when appropriate |
| Key limitation |
Asthma and pulmonary-risk concerns |
Tachycardia and fluid-management considerations |
Variable tolerability and route-dependent use |
Hypertension and cardiovascular contraindications |
| Revenue outlook |
Stable, low-growth |
Larger volume base |
Broad low-cost competition |
Mature niche |
HEMABATE is commercially defensible through clinical positioning and supply reliability, not intellectual property. Its market can remain durable despite low growth because postpartum hemorrhage protocols require access to multiple agents with different contraindication profiles.
What is the geographic coverage and international outlook?
HEMABATE and generic carboprost products are most commercially relevant in markets with hospital-based obstetric care and access to injectable medicines. The United States remains important because of its large hospital procurement system and established treatment protocols.
International demand is shaped by:
- National maternal-health policies.
- Hospital delivery rates.
- Availability of oxytocin and misoprostol.
- Cold-chain and sterile-injectable infrastructure.
- Government tenders and pooled procurement.
- Local regulatory approval.
- Cost sensitivity.
In lower-resource settings, misoprostol may have a stronger practical position because it is easier to store and administer. Carboprost is more likely to remain concentrated in hospitals with trained personnel and injectable-drug infrastructure.
How strong is the HEMABATE commercial estate?
The product estate is commercially durable but financially modest.
| Dimension |
Assessment |
| Patent strength |
Weak or non-existent as a current barrier |
| Regulatory position |
Established FDA-approved product |
| Clinical differentiation |
Meaningful rescue-therapy role |
| Generic pressure |
High |
| Demand stability |
Moderate to high |
| Pricing power |
Low outside shortage conditions |
| Manufacturing complexity |
Meaningful because of sterile injectable requirements |
| Biosimilar risk |
None |
| Litigation risk |
Low for patent litigation; continuing product-liability and manufacturing exposure |
| Revenue growth |
Limited |
| Strategic value |
Higher than standalone revenue may suggest because of emergency-care relevance |
Key Takeaways
- HEMABATE is carboprost tromethamine injection, an established uterotonic for postpartum hemorrhage caused by uterine atony.
- Patent and regulatory exclusivity have expired; generic carboprost competition is the central market reality.
- No active patent estate appears to block generic entry or support significant long-term pricing power.
- Pfizer does not separately disclose HEMABATE revenue, preventing a validated product-level financial forecast from public filings.
- Demand is stable because hospitals must maintain access to rescue uterotonics, but growth is limited by mature use and therapeutic substitution.
- Sterile manufacturing, supply reliability, hospital contracts, and shortage conditions matter more than intellectual property.
- Paragraph IV litigation and biosimilar competition are not material current risks.
- The main commercial upside comes from supply disruption or limited generic availability, not from patent restoration.
- HEMABATE is strategically important as an emergency obstetric product but is unlikely to be a major standalone pharmaceutical revenue contributor.
FAQs
Is HEMABATE still available in the United States?
HEMABATE has an FDA-approved product history, while market availability can vary with manufacturer supply, distributor inventory, and generic carboprost availability. Hospital purchasing decisions may shift between the branded and generic versions.
Is carboprost the same drug as HEMABATE?
Yes. HEMABATE is the branded product containing carboprost tromethamine. FDA-approved generic carboprost tromethamine injections are intended to be therapeutically equivalent when approved for the same conditions.
Can HEMABATE be used in patients with asthma?
Asthma is a major safety concern and is identified in product labeling as a contraindication or serious precaution depending on the clinical circumstances. Clinicians generally select another uterotonic when carboprost-related bronchospasm risk is unacceptable.[1]
Does HEMABATE have orphan-drug exclusivity?
No. HEMABATE is not an orphan biologic or orphan small-molecule product with current orphan exclusivity. Its indications are established obstetric uses.
What is the investment thesis for a generic carboprost manufacturer?
The thesis depends on reliable sterile manufacturing, hospital-contract execution, limited supplier competition, and the ability to maintain supply during shortages. It does not depend on patent exclusivity or a large chronic-use patient population.
References
-
Pfizer Inc. (n.d.). HEMABATE (carboprost tromethamine) injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
-
World Health Organization. (2023). WHO recommendation on the assessment of postpartum blood loss and use of a treatment bundle for postpartum haemorrhage. https://www.who.int/publications/i/item/9789240085394
-
American College of Obstetricians and Gynecologists. (2017). Practice Bulletin No. 183: Postpartum hemorrhage. Obstetrics & Gynecology, 130(4), e168-e186. https://doi.org/10.1097/AOG.0000000000002351
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Pfizer Inc. (2024). Annual report 2023. https://investors.pfizer.com/financials/annual-reports/default.aspx
